Alosetron: a case study in regulatory capture, or a victory for patients' rights?

被引：34

作者：

Moynihan, R ^{[1
]}

机构：

[1] Australian Financial Review, Sydney, NSW 2201, Australia

来源：

BRITISH MEDICAL JOURNAL | 2002年 / 325卷 / 7364期

关键词：

D O I：

10.1136/bmj.325.7364.592

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：592 / 595

页数：4

共 15 条

[1]

[Anonymous], LOS ANGELES TIM 0630

[2] Alosetron for irritable bowel syndrome [J].

Barbehenn, E ;

Lurie, P ;

Wolfe, SM .

LANCET, 2000, 356 (9246) :2009-2009

[3] Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial [J].

Camilleri, M ;

Northcutt, AR ;

Kong, S ;

Dukes, GE ;

McSorley, D ;

Mangel, AW .

LANCET, 2000, 355 (9209) :1035-1040

[4]

*DEP HLTH HUM SERV, 2002, D000674 PID DEP HLTH

[5]

*DEP HLTH HUM SERV, 2002, GASTR DRUGS ADV COMM

[6]

*DEP HLTH HUM SERV, 2000, GASTR DRUGS ADV COMM

[7]

Horton R, 2001, LANCET, V358, P417, DOI 10.1016/S0140-6736(01)05565-9

[8] Lotronex and the FDA: a fatal erosion of integrity [J].

Horton, R .

LANCET, 2001, 357 (9268) :1544-1545

[9] Selling sickness: the pharmaceutical industry and disease mongering [J].

Moynihan, R ;

Heath, I ;

Henry, D .

BRITISH MEDICAL JOURNAL, 2002, 324 (7342) :886-890

[10] FDA advisers warn of more deaths if drug is relaunched [J].

Moynihan, R .

BRITISH MEDICAL JOURNAL, 2002, 325 (7364) :561-561

← 1 2 →